100 related articles for article (PubMed ID: 16249352)
1. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.
Schwartz JD; Sung M; Schwartz M; Lehrer D; Mandeli J; Liebes L; Goldenberg A; Volm M
Oncologist; 2005 Oct; 10(9):718-27. PubMed ID: 16249352
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Katamura Y; Aikata H; Kimura Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Kawakami Y; Takahashi S; Ishikawa M; Hieda M; Kakizawa H; Chayama K
J Gastroenterol Hepatol; 2010 Jun; 25(6):1117-22. PubMed ID: 20074168
[TBL] [Abstract][Full Text] [Related]
6. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
Kuroda M; Kobayashi Y; Urawa N; Yamamoto M; Mifuji R; Araki J; Tanaka H; Horiike S; Itani T; Furjita N; Konishi M; Iwasa M; Kaito M; Adachi Y
Hepatogastroenterology; 2007 Mar; 54(74):518-21. PubMed ID: 17523311
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
10. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
[TBL] [Abstract][Full Text] [Related]
11. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Ch'ang HJ; Hsu C; Chen CH; Chang YH; Chang JS; Chen LT
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):817-25. PubMed ID: 21277098
[TBL] [Abstract][Full Text] [Related]
14. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis.
Chen YY; Yen HH; Chou KC; Wu SS
World J Gastroenterol; 2012 Feb; 18(5):466-71. PubMed ID: 22346253
[TBL] [Abstract][Full Text] [Related]
17. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
18. Low-dose thalidomide treatment for advanced hepatocellular carcinoma.
Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL
Oncology; 2003; 65(3):242-9. PubMed ID: 14657598
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma.
Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW
Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.
Ueshima K; Kudo M; Nagai T; Tatsumi C; Ueda T; Takahashi S; Hatanaka K; Kitai S; Ishikawa E; Inoue T; Hagiwara S; Minami Y; Chung H
Oncology; 2008; 75 Suppl 1():106-13. PubMed ID: 19092279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
